UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Glatiramer Acetate: A Review of its Use in Relapsing-Remitting Multiple Sclerosis and in Delaying the Onset of Clinically Definite Multiple Sclerosis

Drugs (New York, N.Y.), 2010-08, Vol.70 (12), p.1545-1577

2010

Volltextzugriff (PDF)

Glatiramer acetate persists at the injection site and draining lymph nodes via electrostatically-induced aggregation

Journal of controlled release, 2019-01, Vol.293, p.36-47

2019

Volltextzugriff (PDF)

Gut Microbiota in Multiple Sclerosis: Possible Influence of Immunomodulators

Journal of investigative medicine, 2015-06, Vol.63 (5), p.729-734

2015

Volltextzugriff (PDF)

Two decades of glatiramer acetate: From initial discovery to the current development of generics

Journal of the neurological sciences, 2017-05, Vol.376, p.255-259

2017

Volltextzugriff (PDF)

Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients

Expert opinion on pharmacotherapy, 2018-03, Vol.19 (5), p.483-498

2018

Volltextzugriff (PDF)

Electrophysiological and histopathological evaluation of the effectiveness of melatonin and glatiramer acetate for traumatic facial nerve injuries

Injury, 2024-10, Vol.55 (10), p.111719, Article 111719

2024

Volltextzugriff (PDF)

Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: A randomized clinical trial

Acta neurologica Scandinavica, 2021-02, Vol.143 (2), p.178-187

2021

Volltextzugriff (PDF)

An Immunomodulatory Peptide Dendrimer Inspired from Glatiramer Acetate

Angewandte Chemie International Edition, 2021-12, Vol.60 (50), p.26403-26408

International ed. in English, 2021

Volltextzugriff (PDF)

Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing–remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study

Multiple sclerosis, 2017-05, Vol.23 (6), p.818-829

2017

Volltextzugriff (PDF)

Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: A meta-analysis

Neurology, 2020-06, Vol.94 (22), p.e2373

2020

Volltextzugriff (PDF)

Glatiramer Acetate for the Treatment of Multiple Sclerosis: From First-Generation Therapy to Elucidation of Immunomodulation and Repair

Pharmacological reviews, 2024-10, Vol.76 (6), p.1133-1158

2024

Volltextzugriff (PDF)

Glatiramer Acetate Reverses Motor Dysfunction and the Decrease in Tyrosine Hydroxylase Levels in a Mouse Model of Parkinson's Disease

Neuroscience, 2019-08, Vol.414, p.8-27

2019

Volltextzugriff (PDF)

Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results

Multiple sclerosis, 2017-12, Vol.23 (14), p.1909-1917

2017

Volltextzugriff (PDF)

Exploring the effect of glatiramer acetate on cerebral gray matter atrophy in multiple sclerosis

Journal of the neurological sciences, 2023-01, Vol.444, p.120501-120501, Article 120501

2023

Volltextzugriff (PDF)

Glatiramer acetate attenuates depressive/anxiety-like behaviors and cognitive deficits induced by post-weaning social isolation in male mice

Psychopharmacology, 2021-08, Vol.238 (8), p.2121-2132

2021

Volltextzugriff (PDF)

Demonstration of equivalence of a generic glatiramer acetate (Glatopa™)

Journal of the neurological sciences, 2015-12, Vol.359 (1), p.24-34

2015

Volltextzugriff (PDF)

Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study

Journal of neurology, neurosurgery and psychiatry, 2016-10, Vol.87 (10), p.1133-1137

2016

Volltextzugriff (PDF)

Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis

Cochrane database of systematic reviews, 2017-04, Vol.4 (4), p.CD012200-CD012200

2017

Volltextzugriff (PDF)

Nicolau syndrome following subcutaneous glatiramer acetate injection: A case report and review of the literature

Indian journal of pharmacology, 2021-11, Vol.53 (6), p.489-492

2021

Volltextzugriff (PDF)

Compositional differences between Copaxone and Glatopa are reflected in altered immunomodulation ex vivo in a mouse model

Annals of the New York Academy of Sciences, 2017-11, Vol.1407 (1), p.75-89

2017

Volltextzugriff (PDF)

Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition

Journal of neuroimmunology, 2016-01, Vol.290, p.84-95

2016

Volltextzugriff (PDF)

Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry

Journal of neurology, 2018-12, Vol.265 (12), p.2980-2992

2018

Volltextzugriff (PDF)

The Evolving Mechanisms of Action of Glatiramer Acetate

Cold Spring Harbor perspectives in medicine, 2019-02, Vol.9 (2), p.a029249

2019

Volltextzugriff (PDF)

Normocomplementemic urticarial vasculitis in a patient with multiple sclerosis on glatiramer acetate

Journal of neuroimmunology, 2023-07, Vol.380, p.578110-578110, Article 578110

2023

Volltextzugriff (PDF)

1 – 25 von 1.868

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.654)
Mit Volltextzugriff
(1.420)

Publikationsform

Sprache

15 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Glatiramer Acetate
(1.612)
Science & Technology
(1.417)
Humans
(1.362)
Life Sciences & Biomedicine
(1.355)
Multiple Sclerosis
(1.098)
Neurosciences & Neurology
(854)
Peptides - Therapeutic Use
(742)
Female
(712)
Multiple Sclerosis - Drug Therapy
(710)
Clinical Neurology
(691)
Adult
(591)
Male
(582)
Neurosciences
(511)
Immunosuppressive Agents - Therapeutic Use
(495)
Interferon-Beta - Therapeutic Use
(449)
Neurology
(444)
Multiple Sclerosis, Relapsing-Remitting - Drug Therapy
(438)
Middle Aged
(396)
Animals
(317)
Biological And Medical Sciences
(290)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Glatiramer Acetate: A Review of its Use in Relapsing-Remitting Multiple Sclerosis and in Delaying the Onset of Clinically Definite Multiple Sclerosis

Glatiramer acetate persists at the injection site and draining lymph nodes via electrostatically-induced aggregation

Gut Microbiota in Multiple Sclerosis: Possible Influence of Immunomodulators

Two decades of glatiramer acetate: From initial discovery to the current development of generics

Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients

Electrophysiological and histopathological evaluation of the effectiveness of melatonin and glatiramer acetate for traumatic facial nerve injuries

Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: A randomized clinical trial

An Immunomodulatory Peptide Dendrimer Inspired from Glatiramer Acetate

Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing–remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study

Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: A meta-analysis

Glatiramer Acetate for the Treatment of Multiple Sclerosis: From First-Generation Therapy to Elucidation of Immunomodulation and Repair

Glatiramer Acetate Reverses Motor Dysfunction and the Decrease in Tyrosine Hydroxylase Levels in a Mouse Model of Parkinson's Disease

Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results

Exploring the effect of glatiramer acetate on cerebral gray matter atrophy in multiple sclerosis

Glatiramer acetate attenuates depressive/anxiety-like behaviors and cognitive deficits induced by post-weaning social isolation in male mice

Demonstration of equivalence of a generic glatiramer acetate (Glatopa™)

Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study

Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis

Nicolau syndrome following subcutaneous glatiramer acetate injection: A case report and review of the literature

Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis

Compositional differences between Copaxone and Glatopa are reflected in altered immunomodulation ex vivo in a mouse model

Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition

Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry

The Evolving Mechanisms of Action of Glatiramer Acetate

Normocomplementemic urticarial vasculitis in a patient with multiple sclerosis on glatiramer acetate

Suchergebnisse filtern